Treanda

(Bendamustine)

ApprovedSmall molecule

Bendamustine is used to treat certain types of blood cancers, including chronic lymphocytic leukemia and lymphomas. It works by damaging cancer cell DNA to stop them from growing and multiplying.[2] Treanda is currently approved and in use across 40 indications[4].[1]

Treanda is one of 608 small molecule programs targeting Waldenstrom macroglobulinemia. It is currently in Approved.

Indications

239

Total Trials

Active Trials

607

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Waldenstrom MacroglobulinemiaRecruiting

LymphomaWithdrawn

Relapsed/refractoryTerminated

B-Cell Non-Hodgkins LymphomaApproved

Classic Hodgkin LymphomaApproved

MALT LymphomaApproved

Angioimmunoblastic T-Cell LymphomaApproved

Hodgkins LymphomaApproved

Marginal Zone B-Cell LymphomaApproved

Small Cell Lung CancerApproved

Waldenstrom MacroglobulinemiaApproved

Recruiting

LymphomaApproved

Withdrawn

Relapsed/refractoryPhase 2

Terminated

B-Cell Non-Hodgkins LymphomaApproved

Approved

Classic Hodgkin LymphomaApproved

Approved

MALT LymphomaApproved

Approved

Angioimmunoblastic T-Cell LymphomaApproved

Approved

Hodgkins LymphomaApproved

Approved

Marginal Zone B-Cell LymphomaApproved

Approved

Small Cell Lung CancerApproved

Approved

Showing 10 of 40 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Treanda

AAzurity Pharmaceuticals

Approved

52 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Multiple Myeloma

NCT03352765

Q1 2027

Phase 3Active, not recruiting

TED

NCT02972840

Q2 2027

Phase 1/2Active, not recruiting

Follicular Lymphoma

NCT05551936

Phase 3Active, not recruiting

Chronic Lymphocytic Leukemia

NCT04666038

Recruiting

Real-World Study

NCT05899621

Q3 2027

Phase 3Recruiting

Treatment

NCT06496308

Clinical

Trials by Indication[1]

Lymphoma46 trials

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Completed·PPeter Moosmann·Phase 1/2·NCT00426855·12 enrolled

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Not yet recruiting·FFox Chase Cancer Center·Phase 2·NCT06557330·24 enrolled

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Completed·—·Phase 1·NCT02257242·11 enrolled

Show 43 more trials

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Completed·EEmory University·Phase 1/2·NCT03739619·3 enrolled

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

Unknown status·SState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia·Phase 2·NCT03315520·100 enrolled

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01974440·403 enrolled

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04882163

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1/2·NCT04673617·45 enrolled

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Active, not recruiting·TTessa Therapeutics·Phase 2·NCT04268706·97 enrolled

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Completed· Roche logo

Roche·Phase 2·NCT02187861·163 enrolled

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 3·NCT05711628

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01429025·26 enrolled

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02927769·72 enrolled

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01929265·73 enrolled

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Completed· Novartis logo

Novartis·Phase 2·NCT01294579·49 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Completed·FFate Therapeutics·Phase 1·NCT05950334·20 enrolled

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Withdrawn·SSecuraBio·Phase 3·NCT02576275

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Completed·UUniversity of Rochester·Phase 2·NCT00547534·31 enrolled

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn·FFate Therapeutics·Phase 1·NCT05934097

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Terminated· Gilead logo

Gilead·Phase 3·NCT01732926·475 enrolled

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Terminated· Takeda logo

Takeda·Phase 1·NCT02954406·43 enrolled

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01716806·131 enrolled

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04083495·20 enrolled

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Completed·AAptevo Therapeutics·Phase 1·NCT01317901·12 enrolled

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting·SSecuraBio·Phase 3·NCT06522737·124 enrolled

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Unknown status·—·Phase 2·NCT01884441·59 enrolled

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Unknown status·SShandong Lanjin Pharmaceuticals Co.,Ltd·Phase 3·NCT01570049·100 enrolled

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT02059239·34 enrolled

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma

Unknown status·IIstituto Nazionale Tumori IRCCS - Fondazione G. Pascale·Phase 1/2·NCT01412307·36 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT00959686·45 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Completed·UUniversity of Kansas Medical Center·Phase 1·NCT01022021·17 enrolled

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT01874054·55 enrolled

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not yet recruiting·XXiuhua Sun·Phase 4·NCT06761911·100 enrolled

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06465446·202 enrolled

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02414568·90 enrolled

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Completed· Roche logo

Roche·Phase 3·NCT01332968·1,401 enrolled

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06006117·260 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Completed· Incyte logo

Incyte·Phase 1·NCT03424122·50 enrolled

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01029730·55 enrolled

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Terminated· Bayer logo

Bayer·Phase 3·NCT02626455·551 enrolled

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed· AbbVie logo

AbbVie·Phase 1·NCT01594229·60 enrolled

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Withdrawn·UUniversity of Arizona·Phase 2·NCT02623920

Chronic Lymphocytic Leukemia29 trials

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Completed·NNicole Lamanna·Phase 2·NCT03609593·42 enrolled

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Completed·AAptevo Therapeutics·Phase 1/2·NCT01188681·79 enrolled

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 2·NCT02071225·72 enrolled

Show 26 more trials

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Completed· Roche logo

Roche·Phase 3·NCT04285567·166 enrolled

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Completed·GGerman CLL Study Group·Phase 3·NCT02950051·926 enrolled

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05023980·309 enrolled

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Completed· Roche logo

Roche·Phase 1·NCT01300247·41 enrolled

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

Not yet recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07003464·30 enrolled

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT00951457·20 enrolled

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed· Gilead logo

Gilead·Phase 1·NCT01088048·241 enrolled

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01096992·51 enrolled

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed· AbbVie logo

AbbVie·Phase 3·NCT03406156·120 enrolled

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Completed· Gilead logo

Gilead·Phase 3·NCT01569295·416 enrolled

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Terminated· Gilead logo

Gilead·Phase 3·NCT01980888·311 enrolled

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

Withdrawn·UUniversity of Kentucky·Phase 2·NCT00758693

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT02194374

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00274989·195 enrolled

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Completed·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2/3·NCT01423032·96 enrolled

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06205290

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04666038·238 enrolled

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00899431·39 enrolled

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·UUniversity of Washington·Phase 2·NCT04155840·1 enrolled

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02733042·106 enrolled

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT01352312·10 enrolled

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00769522·564 enrolled

A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)

Completed· Roche logo

Roche·Phase 4·NCT01056510·357 enrolled

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01466153·183 enrolled

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 3·NCT01905943·979 enrolled

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 2·NCT02320487·102 enrolled

Multiple Myeloma19 trials

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT02315157

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04674813·130 enrolled

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 1/2·NCT04762745·56 enrolled

Show 16 more trials

Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Unknown status·LLiao Aijun·Phase 3·NCT05006469·10 enrolled

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Terminated·—·Phase 1/2·NCT02002598·23 enrolled

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Terminated·LLoyola University·Phase 1/2·NCT01484626·3 enrolled

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Completed·CCephalon·Phase 1/2·NCT00920855·40 enrolled

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Unknown status·CCristina Gasparetto·Phase 1/2·NCT01754402·56 enrolled

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT00916058·57 enrolled

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Terminated·SSherif Farag, MB, BS·Phase 1/2·NCT01177683·32 enrolled

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01056276·59 enrolled

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·PParameswaran Hari·Phase 1/2·NCT02477215·38 enrolled

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Completed·NNoah Merin·Phase 1·NCT03524235·20 enrolled

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03352765·28 enrolled

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Completed·—·Phase 2·NCT01701076·50 enrolled

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Completed·RRobert Redner, MD·Phase 1·NCT01042704·29 enrolled

FT576 in Subjects With Multiple Myeloma

Completed·FFate Therapeutics·Phase 1·NCT05182073·31 enrolled

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 2·NCT01376401·60 enrolled

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT04083898·15 enrolled

Mantle Cell Lymphoma14 trials

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Completed·PPrECOG, LLC.·Phase 2·NCT03834688·33 enrolled

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01776840·523 enrolled

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Withdrawn· Incyte logo

Incyte·Phase 3·NCT04849715

Show 11 more trials

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Recruiting·IInnoCare Pharma Inc.·Phase 3·NCT06363994·476 enrolled

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Completed·CCephalon·Phase 3·NCT01073163·54 enrolled

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT03311126·21 enrolled

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Unknown status·SSamsung Medical Center··NCT04127916·40 enrolled

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT01661881·23 enrolled

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04002297·510 enrolled

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting·EEastern Cooperative Oncology Group·Phase 2·NCT01415752·373 enrolled

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Recruiting·CChristine Ryan·Phase 2·NCT06854003·60 enrolled

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT03623373·13 enrolled

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT02728531·18 enrolled

Diffuse Large B-Cell Lymphoma13 trials

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Recruiting·GGuangzhou Lupeng Pharmaceutical Company LTD.·Phase 2·NCT07189065·150 enrolled

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Withdrawn· Roche logo

Roche·Phase 2·NCT01423539

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·PPharmatech·Phase 2·NCT00831597·61 enrolled

Show 10 more trials

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Completed· Incyte logo

Incyte·Phase 2/3·NCT02763319·453 enrolled

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Completed· Roche logo

Roche·Phase 3·NCT01724021·743 enrolled

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02594163·25 enrolled

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01626352·22 enrolled

A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06554600·36 enrolled

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Terminated· Roche logo

Roche·Phase 3·NCT04236141·42 enrolled

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01234467·23 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04607772

56 more indications

Follicular Lymphoma11 trials

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Active, not recruiting·VVaishalee Kenkre·Phase 1/2·NCT05551936·42 enrolled

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06757894·50 enrolled

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT00636792·73 enrolled

Show 8 more trials

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 4·NCT03817853·114 enrolled

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Completed· Roche logo

Roche·Phase 3·NCT01889069·159 enrolled

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed·PProf. Dr. Wolfgang Hiddemann·Phase 2·NCT03492775·46 enrolled

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06961500·133 enrolled

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00901927·14 enrolled

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Completed·—·Phase 2·NCT01234766·39 enrolled

Relapsed/Refractory4 trials

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Terminated·NNYU Langone Health·Phase 2·NCT01315873·24 enrolled

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT04892277·25 enrolled

CyBeR Association in Relapsed/Refractory DLBCL

Unknown status·UUniversity Hospital, Caen·Phase 2·NCT02758925·78 enrolled

Show 1 more trial

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL

Completed·GGerman CLL Study Group·Phase 2·NCT03787264·46 enrolled

Breast Cancer3 trials

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT01891227·40 enrolled

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 1·NCT00661739·38 enrolled

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 1/2·NCT00834678·11 enrolled

Relapsed or Refractory3 trials

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Completed·CCephalon·Phase 1·NCT00863850·6 enrolled

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT03593018·86 enrolled

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Unknown status·MMunich Municipal Hospital·Phase 2·NCT02320383·27 enrolled

Monotherapy2 trials

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated·FFate Therapeutics·Phase 1·NCT04245722·98 enrolled

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

Terminated· Novartis logo

Novartis·Phase 3·NCT01077518·346 enrolled

Macroglobulinemia2 trials

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07169565·21 enrolled

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Unknown status·SShanghai Changzheng Hospital·Phase 2·NCT05979948·60 enrolled

Leukemia2 trials

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03856216·15 enrolled

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT02799147·27 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT04223765·20 enrolled

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05624554·300 enrolled

TIA2 trials

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Completed·GGerman CLL Study Group·Phase 2·NCT02689141·66 enrolled

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed·GGerman CLL Study Group·Phase 2·NCT02345863·66 enrolled

T-cell non-Hodgkin lymphoma2 trials

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Not yet recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT07225985·50 enrolled

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Terminated·WWake Forest University Health Sciences·Phase 2·NCT04217317·6 enrolled

AL amyloidosis1 trial

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Completed·—·Phase 2·NCT01222260·40 enrolled

Acute Lymphoblastic Leukemia1 trial

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT01649622

Non-Hodgkins Lymphoma1 trial

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Terminated·TTG Therapeutics, Inc.·Phase 2/3·NCT02793583·710 enrolled

APL1 trial

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Completed·UUniversity of Arizona·Phase 1·NCT02996773·50 enrolled

Carboplatin1 trial

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT01458366·38 enrolled

TED1 trial

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Active, not recruiting·AAcerta Pharma BV·Phase 3·NCT02972840·635 enrolled

Advanced Solid Tumors1 trial

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Recruiting·FFate Therapeutics·Phase 1·NCT06241456·351 enrolled

CLL/SLL1 trial

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Recruiting·DDizal (Jiangsu) Pharmaceutical Co., Ltd.·Phase 3·NCT07139873·250 enrolled

Efficacy and Safety1 trial

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Completed·AAzienda Ospedaliera di Bolzano·Phase 2·NCT01526694·30 enrolled

Advanced Hematologic Malignancies1 trial

FT516 in Subjects With Advanced Hematologic Malignancies

Terminated·FFate Therapeutics·Phase 1·NCT04023071·72 enrolled

Advanced Cancers1 trial

Bendamustine and Bevacizumab for Advanced Cancers

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01152203·59 enrolled

Indolent B-cell Non-Hodgkin's Lymphoma1 trial

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Completed· Novartis logo

Novartis·Phase 1·NCT01691807·30 enrolled

Function1 trial

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

Completed·—·Phase 1·NCT01832922·8 enrolled

Efficacy1 trial

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Completed·PPolish Lymphoma Research Group·Phase 2·NCT03615664·115 enrolled

CHOP1 trial

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Completed·UUniversity of Giessen·Phase 3·NCT00991211·549 enrolled

B-cell Malignancies1 trial

FT819 in Subjects With B-cell Malignancies

Active, not recruiting·FFate Therapeutics·Phase 1·NCT04629729·54 enrolled

Chronic Lymphocytic Leukaemia (CLL)1 trial

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Completed· Novartis logo

Novartis·Phase 2·NCT01520922·99 enrolled

Stem Cell Transplantation1 trial

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01490723·20 enrolled

Nivolumab1 trial

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting·TTessa Therapeutics·Phase 1·NCT05352828·15 enrolled

ART1 trial

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT03336333·590 enrolled

Ovarian Cancer1 trial

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Recruiting·MMayo Clinic·Phase 1·NCT06483048·12 enrolled

T Cells1 trial

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03602157·43 enrolled

Induction Chemotherapy1 trial

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00974233·34 enrolled

Stem Cell Transplant1 trial

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00880815·60 enrolled

Renal Failure1 trial

Optimising Renal Outcome in Myeloma Renal Failure

Completed·OOxford University Hospitals NHS Trust·Phase 2·NCT02424851·31 enrolled

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT06191887·27 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Radiation Therapy1 trial

Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

Completed·JJohn Grecula·Phase 1·NCT00837928·18 enrolled

Treatment1 trial

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Recruiting·RRuijin Hospital·Phase 3·NCT06496308·78 enrolled

AIN1 trial

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Completed·GGerman CLL Study Group·Phase 2·NCT02401503·66 enrolled

Hematologic Malignancies1 trial

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT01871675·48 enrolled

NHL1 trial

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Terminated·MMEI Pharma, Inc.·Phase 3·NCT04745832·82 enrolled

Dexamethasone1 trial

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Unknown status·GGruppo Italiano Studio Linfomi·Phase 1/2·NCT01686386·60 enrolled

Myeloma1 trial

Bendamustine and Melphalan in Myeloma

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03187223·120 enrolled

Induction Therapy1 trial

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01754857·36 enrolled

Infusion1 trial

Compassionate Use Re-Infusion of ATLCAR.CD30

No longer available·UUNC Lineberger Comprehensive Cancer Center··NCT03914885

Relapsed or Refractory Hematologic Malignancies1 trial

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01900509·16 enrolled

Brain Metastases From Solid Tumors1 trial

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00879073·12 enrolled

Refractory1 trial

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Unknown status·UUniversity of Magdeburg·Phase 2·NCT00385125·30 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Recruiting·TTr1X, Inc.·Phase 1/2·NCT07477639·39 enrolled

Autoimmune Disease1 trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting·FFate Therapeutics·Phase 1·NCT06308978·244 enrolled

Prostate Cancer1 trial

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT06094842

Acute Leukemia1 trial

Bendamustine in Acute Leukemia and MDS

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00790855·27 enrolled

Lenalidomide1 trial

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Completed·MMassachusetts General Hospital·Phase 1·NCT01400685·34 enrolled

CLL1 trial

GIMEMA CLL0809 Study (BendOfa)

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01244451·49 enrolled

Brentuximab Vedotin1 trial

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02499627·43 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 20, 2008

TREANDA

NDA NDA022249

Apr 22, 2009

TREANDA

NDA NDA022249

May 1, 2009

TREANDA

NDA NDA022249

Feb 26, 2010

TREANDA

NDA NDA022249

Dec 21, 2010

TREANDA

NDA NDA022249

Jun 26, 2012

TREANDA

NDA NDA022249

Aug 28, 2013

TREANDA

NDA NDA022249

Sep 13, 2013

TREANDA

NDA NDA022249

Mar 27, 2014

TREANDA

NDA NDA022249

Mar 10, 2015

TREANDA

NDA NDA022249

Jul 8, 2015

TREANDA

NDA NDA022249

Sep 2, 2015

TREANDA

NDA NDA022249

Nov 5, 2015

TREANDA

NDA NDA022249

Dec 7, 2015

BENDEKA

NDA NDA208194

Oct 18, 2016

TREANDA

NDA NDA022249

Dec 15, 2017

TREANDA

NDA NDA022249

May 15, 2018

BELRAPZO

NDA NDA205580

Nov 21, 2019

TREANDA

NDA NDA022249

Jun 10, 2021

TREANDA

NDA NDA022249

Oct 25, 2022

TREANDA

NDA NDA022249

Dec 7, 2022

VIVIMUSTA

NDA NDA212209

Dec 7, 2022

BENDAMUSTINE HYDROCHLORIDE

NDA NDA215033

Dec 15, 2022

BENDAMUSTINE HYDROCHLORIDE

NDA NDA216078

Dec 15, 2022

BENDAMUSTINE HYDROCHLORIDE

NDA NDA211530

Jul 3, 2025

BENDAMUSTINE HYDROCHLORIDE

NDA NDA219014

Sources

References

[1]
ClinicalTrials.gov — 239 trial records for Bendamustine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Treanda drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Bendamustine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Bendamustine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219014). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Treanda. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Azurity Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAzurity Pharmaceuticals

Patent Landscape[6]

Patent Cliff

Mar 26, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8895756Jan 12, 2026

8609863Jan 12, 2026

8791270Jan 12, 2026

8609863*PEDJul 12, 2026

8791270*PEDJul 12, 2026

36 more patents

8895756*PEDJul 12, 2026

8669279Mar 26, 2029

8883836Mar 26, 2029

8445524Mar 26, 2029

9533955Mar 26, 2029

8344006Sep 23, 2029

9533955*PEDSep 26, 2029

8445524*PEDSep 26, 2029

8883836*PEDSep 26, 2029

8669279*PEDSep 26, 2029

8344006*PEDMar 23, 2030

8436190Oct 26, 2030

12350257Jan 28, 2031

11103483Jan 28, 2031

11844783Jan 28, 2031

9572797Jan 28, 2031

10010533Jan 28, 2031

12138248Jan 28, 2031

9265831Jan 28, 2031

11872214Jan 28, 2031

9572796Jan 28, 2031

8436190*PEDApr 26, 2031

8609707Aug 11, 2031

9572887Mar 15, 2033

9000021Mar 15, 2033

9597398Mar 15, 2033

9597399Mar 15, 2033

9034908Mar 15, 2033

9597397Mar 15, 2033

9579384Mar 15, 2033

10052385Mar 15, 2033

9144568Mar 15, 2033

11707450Jul 29, 2042

11844784Jul 29, 2042

12419867Jul 29, 2042

12208086Jul 29, 2042

Treanda

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Lymphoma46 trials

Chronic Lymphocytic Leukemia29 trials

Multiple Myeloma19 trials

Mantle Cell Lymphoma14 trials

Diffuse Large B-Cell Lymphoma13 trials

Follicular Lymphoma11 trials

Relapsed/Refractory4 trials

Breast Cancer3 trials

Relapsed or Refractory3 trials

Monotherapy2 trials

Macroglobulinemia2 trials

Leukemia2 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials

TIA2 trials

T-cell non-Hodgkin lymphoma2 trials

AL amyloidosis1 trial

Acute Lymphoblastic Leukemia1 trial

Non-Hodgkins Lymphoma1 trial

APL1 trial

Carboplatin1 trial

TED1 trial

Advanced Solid Tumors1 trial

CLL/SLL1 trial

Efficacy and Safety1 trial

Advanced Hematologic Malignancies1 trial

Advanced Cancers1 trial

Indolent B-cell Non-Hodgkin's Lymphoma1 trial

Function1 trial

Efficacy1 trial

CHOP1 trial

B-cell Malignancies1 trial

Chronic Lymphocytic Leukaemia (CLL)1 trial

Stem Cell Transplantation1 trial

Nivolumab1 trial

ART1 trial

Ovarian Cancer1 trial

T Cells1 trial

Induction Chemotherapy1 trial

Stem Cell Transplant1 trial

Renal Failure1 trial

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

Real-world Study1 trial

Radiation Therapy1 trial

Treatment1 trial

AIN1 trial

Hematologic Malignancies1 trial

NHL1 trial

Dexamethasone1 trial

Myeloma1 trial

Induction Therapy1 trial

Infusion1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Brain Metastases From Solid Tumors1 trial

Refractory1 trial

Secondary Progressive Multiple Sclerosis1 trial

Autoimmune Disease1 trial

Prostate Cancer1 trial

Acute Leukemia1 trial

Lenalidomide1 trial

CLL1 trial

Brentuximab Vedotin1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News